
Super smart data entry for clinical research sites — move source to EDC faster.
By Tanmay Verma, Founder · Last verified 03 Jul 2026
In short
Gleam — Super smart data entry for clinical research sites — move source to EDC faster. Best for Clinical research coordinators seeking to cut data entry time, Site directors wanting sponsor-independent workflow automation, Sites using multiple EDCs and eSource systems. Contact Sales pricing.
See what real users actually say. We scan live discussions, reviews and complaints across the web and hand you an honest verdict — in under a minute.
3 free scans · no card needed · downloadable report
Gleam solves a real pain point for clinical research sites by automating data entry without heavy integration. Its site-first, no-sponsor-approval model is a strong differentiator, though paper/PDF support is still in waitlist mode. Worth a demo for CRCs drowning in copy-paste.
Compare with: Gleam vs BEKHealth, Gleam vs Tempus, Gleam vs Recursion
Last verified: July 2026
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
67 mentions across 4 sources (Hacker News, Product Hunt, App Store, Lemmy).
How likely is Gleam to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Gleam is a browser-based tool that automates data entry for clinical research sites, helping coordinators move data from source systems (including paper/PDF and electronic health records) into EDC CRFs with minimal manual effort. It works as a browser extension that identifies study, visit, and patient context, maps data to the correct CRF fields, and runs quality checks before proposing entries. No custom integrations or sponsor approval are needed to start. Built for clinical research coordinators and site staff, Gleam reduces transcription errors and frees up time for patient care. It uses a 'verify then trust' approach, flagging uncertain fields for manual review and showing the source behind each value. Gleam contracts directly with sites, not sponsors, giving sites control over their workflow. The tool supports browser-based sources and EDCs, with paper/PDF support available now via a 'Notify me' waitlist. Its AI approach is FDA- and sponsor-friendly, as highlighted in recent blog posts and podcasts.
Gleam is refreshingly focused. It targets a single, painful workflow—moving source data into EDC CRFs—and does it without requiring custom integrations or sponsor sign-off. That alone makes it worth a look for site directors who've been burned by over-engineered platforms. The browser extension approach is clever; it sits atop existing systems rather than replacing them. The 'verify then trust' philosophy is also smart—AI suggestions are surfaced with source traceability, and low-confidence fields are flagged for manual review. This builds trust with auditors and coordinators alike. Where Gleam falls short today: paper/PDF source support is not yet live (only a waitlist). If your site relies heavily on paper sources, you'll have to wait. Also, it's browser-only—no offline or desktop app, so inconsistent internet could be a bottleneck. Compared to alternatives like eSource platforms or manual entry with data validation tools, Gleam requires less setup but offers less control for sponsors or CROs. It's squarely a site tool, and that's its strength. We'd recommend it for sites with browser-based EDCs and eSource who want immediate productivity gains. Skip it if you need sponsor oversight features or if your workflow is predominantly offline or paper-based until that support matures.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Common stack mates teams adopt alongside Gleam, with the specific reason each pairing earns its keep.
Used Gleam? Help shape our editorial sentiment research.